Evidence map›Paper›PMID 35156343›Full record

ReviewDiagnostic cytopathology2022

Cytological and molecular characterization of secretory breast carcinoma.

Irene Carretero-Barrio, Almudena Santón, Tamara Caniego Casas, Elena López Miranda, Maria Eugenia Reguero-Callejas, Belén Pérez-Mies, Amparo Benito, José Palacios

Abstract readCase ReportsReview
In one paragraph

Review in Diagnostic cytopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Rare Breast Cancers Review.Healthcare (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Irene Carretero-BarrioPathology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0000-0003-1986-2965
Almudena SantónPathology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Tamara Caniego CasasPathology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Elena López MirandaOncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Maria Eugenia Reguero-CallejasPathology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Belén Pérez-MiesPathology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0000-0001-5764-5182
Amparo BenitoPathology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0000-0002-1312-4892
José PalaciosPathology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.ORCID https://orcid.org/0000-0002-6730-5066

Funding

Centro de Investigación Biomédica en Red de CáncerEuropean Regional Development FundInstituto de Salud Carlos III
6 · The paper itself

Abstract

Secretory breast carcinoma is a rare neoplasm, histologically well-characterized, and secondary to ETV6-NTRK3 gene fusion, whose cytological features are scarcely described in the literature. We report the case of a woman with a history of secretory breast carcinoma 8 years before, who presented a periareolar nodule. A recurrence was diagnosed by fine-needle aspiration based on the cytomorphological features and pan-TRK immunocytochemistry on the cell block, and the patient underwent a mastectomy. The histology and molecular studies performed on the surgical specimen (immunohistochemistry, FISH and NGS) confirmed the diagnosis. Cytological smears showed abundant epithelial cellularity, in groups and single cells. These cells showed moderate atypia, with abundant cytoplasm. We observed intracytoplasmic inclusions and extracellular metachromatic globules. Immunocytochemical and immunohistochemical studies showed a triple negative breast tumour. NTRK overexpression was demonstrated with immunocytochemistry against pan-TRK on the cell block, as well as with immunohistochemistry in the surgical specimen. NTRK3 rearrangement was proved by FISH. In the primary tumour and in the recurrence, we demonstrated ETV6-NTRK3 fusion by NGS. After conducting a literature review, we have found 26 articles describing the cytological features of secretory breast carcinoma in 33 patients. The smears were described as groups of epithelial cells with vacuolated cytoplasm, single signet ring cells and a globular extracellular secretion. In only two cases molecular confirmation of the diagnosis with ETV6-NTRK3 fusion was proven, although not in the cytological specimen, but in the subsequent biopsy. The distinct cytological features of secretory breast carcinoma can help in its diagnosis, thus guiding the molecular studies. This is the first reported case that proves TRK overexpression, as a fusion surrogate, in the cytological sample.

Indexed as

Breast NeoplasmsBiomarkers, TumorCarcinomaFemaleHumansMastectomyOncogene Proteins, FusionBiomarkers, TumorOncogene Proteins, Fusionmolecular diagnosisNGSNTRKsecretory breast carcinoma

Identifiers

PMID35156343
PMCPMC9303577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.